lowered second-quarter guidance Tuesday, citing a slowdown in breast-implant sales.
The company expects to earn 24 cents or 25 cents a share on sales of $112 million to $115 million in the three months to Sept. 30. Analysts expected earnings of 34 cents a share on sales of $120.7 million.
"In the latter part of the second quarter, we saw sales growth slow in our aesthetics segment. We believe this was primarily related to women delaying breast augmentation in advance of the potential U.S. approval of our silicone gel breast implant products, following our July 28th announcement that we received an FDA approvable letter," Mentor said.
For the fiscal year ending next March, the company expects to earn $1.60 to $1.65 a share on sales that are up by a double-digit percentage over 2005's $473.4 million. Analysts surveyed by Thomson First Call were predicting earnings of $1.68 a share on sales of $528.3 million.
The stock was halted for after-hours trading after closing at $49.72.